Veeva Systems and OpenEvidence Partner to Launch AI-Powered Clinical Trial Access Platform
核心洞察
Veeva Systems (搜索) and OpenEvidence (搜索) announced a long-term partnership to create Open Vista (搜索), an AI-powered platform designed to increase patient access to clinical trials and accelerate drug discovery.
OpenEvidence (搜索) currently serves more than 40% of U.S. physicians through its clinical decision support AI platform, which is used by over 10,000 hospitals and medical centers nationwide.
The Open Vista (搜索) platform aims to bridge life sciences companies, patients, and physicians by leveraging AI to connect patients with relevant clinical trials and improve adoption of existing approved medicines.
Veeva Systems (搜索) (NYSE: VEEV) and OpenEvidence (搜索) announced the formation of a strategic long-term partnership to jointly develop and market Open Vista (搜索), an artificial intelligence-powered platform designed to revolutionize patient access to clinical trials and accelerate drug discovery processes. The collaboration aims to bridge the gap between life sciences companies developing life-saving medicines, patients seeking treatment options, and the physicians who care for them.
AI-Driven Clinical Trial Matching
Open Vista (搜索) will utilize artificial intelligence to address critical challenges in clinical trial enrollment and drug development. The platform is designed to increase patient access to clinical trials, accelerate drug discovery through enhanced understanding of unmet medical needs, and improve comprehension and adoption of existing approved medicines to deliver better patient outcomes.
"For many patients with serious illnesses who have exhausted first and second line therapies, clinical trials are their most promising form of healthcare," said Daniel Nadler, CEO of OpenEvidence (搜索). "In partnering with Veeva, we now have a unique opportunity to go a step further and leverage the power of AI to connect physicians and patients to relevant clinical trials and cutting-edge therapies."
Established Clinical Decision Support Foundation
OpenEvidence (搜索) brings significant market penetration to the partnership, with more than 40% of U.S. physicians actively using its point-of-care clinical decision support AI. The platform currently serves as the most widely used medical search engine among U.S. clinicians and is trusted by hundreds of thousands of verified healthcare professionals for high-stakes clinical decisions at the point of care.
The company's clinical decision support platform is grounded in peer-reviewed medical literature and is actively used by more than 10,000 hospitals and medical centers across the United States. OpenEvidence (搜索) has positioned itself as an accelerator for the dissemination of medical knowledge, streamlining the translation of medical research from bench to bedside.
Strategic Industry Integration
Veeva Systems (搜索), which serves more than 1,500 customers ranging from the world's largest biopharmaceutical companies to emerging biotechs, views the partnership as a crucial step in the AI evolution of life sciences. Peter Gassner, CEO of Veeva, emphasized the strategic importance of the collaboration in the current technological landscape.
"We are very excited about our long-term partnership with OpenEvidence (搜索) as we enter the AI chapter in life sciences," Gassner stated. "Combining the strengths of Veeva and OpenEvidence, we can use AI to bridge life sciences companies making life-saving medicines, patients, and the physicians who treat them."
Timeline and Market Impact
The first Open Vista (搜索) product offerings are expected to be released in 2026, providing the pharmaceutical industry with new tools to enhance clinical trial efficiency and patient matching. The platform aims to help life sciences companies accelerate the development of effective new treatments while enabling more patients to participate in clinical trials.
The partnership represents a significant convergence of clinical decision support technology and life sciences infrastructure, potentially transforming how patients access experimental therapies and how pharmaceutical companies identify and recruit suitable trial participants.